bimekizumab (UCB4940) - UCB
Bimekizumab: Acceptance of regulatory submission for psoriasis at the end of Q3 2020 (UCB) - Jul 28, 2020 - H1 2020 Results 
Regulatory Psoriasis
https://www.ucb.com/_up/ucb_com_ir/documents/2020_HY_presentation_-_final.pdf
 
Jul 28, 2020
 
 
6c768744-652c-435b-a628-1312181bece3.png